Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13122992 | 0.89 | PTGDR (0.80) | TBXA2RPTGDR | |
| SCHEMBL13122993 | 0.89 | TBXA2R (0.80) | TBXA2RPTGDR | |
| SCHEMBL4466127 | 0.88 | TBXA2R (0.79) | TBXA2RPTGDR | |
| SCHEMBL991127 | 0.86 | TBXA2R (1.00) | TBXA2RPTGDR | |
| SCHEMBL4321521 | 0.85 | TBXA2R (0.75) | TBXA2RPTGDR | |
| SCHEMBL3148394 | 0.85 | TBXA2R (0.73) | TBXA2RPTGDR | |
| SCHEMBL5079585 | 0.84 | TBXA2R (0.79) | TBXA2RPTGDR | |
| SCHEMBL12923781 | 0.82 | TBXA2R (0.80) | TBXA2RPTGDR | |
| SCHEMBL1042323 | 0.78 | PTGDR (1.00) | TBXA2RPTGDR | |
| SCHEMBL14449868 | 0.78 | PTGDR (1.00) | TBXA2RPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-12-01 | — | — | US | disclosed |
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-12-01 | — | — | US | disclosed |
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3175856-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS | The Trustees of the University of Pennsylvania (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2037967-B1 | PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS FOR TREATING ANDROGENETIC ALOPECIA | UNIV PENNSYLVANIA (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160346186-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-12-01 | — | — | US | disclosed |
| US-9254293-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-02-09 | — | — | US | disclosed |
| US-9254293-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-02-09 | — | — | US | disclosed |
| US-7241792-B2 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241792-B2 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2007075749-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2007035478-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007027532-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007002557-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006089309-A2 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | CHENG KANG (US) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346186-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | AR, BPHL, PTGS2 | TBXA2R 888/4885PTGDR 10/4885 |
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | AR, BPHL, PTGS2 | TBXA2R 888/4885PTGDR 10/4885 |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ACE, ACE2, AGTR2 | TBXA2R 434/4885PTGDR 509/4885 |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | LDLR, HCAR1, FFAR1 | TBXA2R 37/4885PTGDR 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.